What Mounjaro is

Mounjaro is Eli Lilly's brand name for tirzepatide, a once-weekly injectable peptide that activates both GLP-1 and GIP receptors. It is the only approved dual-incretin agonist currently on the market. For deeper detail on the molecule itself — mechanism, full trial evidence, dosing — see our tirzepatide guide.

The Indian launch — what happened and what it meant

Eli Lilly launched Mounjaro in India in March 2025, in single-dose vials at 2.5 mg and 5 mg, following marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO). India was the first major emerging market outside the US, EU, and Japan to receive Mounjaro — a significant decision that reflected both India's vast diabetes and obesity burden and the maturity of its specialty pharmacy network.

In June 2025, the CDSCO approved the Mounjaro KwikPen, a multi-dose prefilled pen designed for once-weekly self-injection. The full dose range — 2.5, 5, 7.5, 10, 12.5, and 15 mg — has progressively become available across major Indian cities through licensed pharmacies and authorised online channels.

Talk to an AIIMS-trained doctor.

2-minute eligibility test. Free. We'll see if Kaivo is the right fit for you.

What CDSCO approved

The Indian regulatory approval covers two indications:

  1. Type 2 diabetes mellitus — as an adjunct to diet and exercise in adults with inadequate glycaemic control.
  2. Chronic weight management — for adults with a BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, or cardiovascular disease), in addition to a reduced-calorie diet and increased physical activity.

For South Asians, these BMI thresholds are commonly adjusted lower (≥25 and ≥23 respectively) in clinical practice in line with ICMR and Diabetes India guidance, reflecting the lower BMI at which Indians develop metabolic disease. See our diabetes guide for the South Asian context.

Mounjaro vs Wegovy — the head-to-head question

Mounjaro is tirzepatide; Wegovy is semaglutide 2.4 mg. Wegovy launched in India in June 2025, including as the Poviztra co-brand through Novo Nordisk's partnership with Emcure.

There has been no direct randomised trial of Mounjaro vs Wegovy in obesity to date. The closest available comparison is SURPASS-2 (Frías et al., NEJM 2021) — tirzepatide vs semaglutide 1 mg in T2D — where all three tirzepatide doses produced greater HbA1c and weight reductions than semaglutide. SURPASS-2 used the T2D dose of semaglutide (1 mg), not the obesity dose (2.4 mg), so it does not perfectly translate to obesity treatment.

Cross-trial comparisons (acknowledged as imperfect):

On average, tirzepatide produces deeper weight loss; semaglutide has a longer record of cardiovascular outcomes data (SELECT in non-diabetic obesity, SUSTAIN-6 in diabetes, FLOW in CKD). Both are excellent drugs.

Mounjaro vs Ozempic — clarifying the confusion

This is where patients are most often confused.

They are different molecules. They are not interchangeable. Ozempic and Wegovy are the same molecule (semaglutide) at different doses for different indications, while Mounjaro is a separate molecule altogether. See our semaglutide guide for the Ozempic/Wegovy/Rybelsus family in detail.

Mounjaro vs generic semaglutide

Following the expiry of Novo Nordisk's semaglutide compound patent in India on 20 March 2026, more than thirty Indian companies have introduced approved generic semaglutide products. Tirzepatide remains under patent protection in India.

The clinical comparison reduces to: generic semaglutide gives you the well-validated semaglutide molecule via various Indian manufacturers; Mounjaro gives you the dual-incretin advantage of tirzepatide, manufactured by Eli Lilly. Choice depends on clinical goals, tolerability, availability, and individual response.

Mounjaro vs Rybelsus

Rybelsus is oral semaglutide — a daily tablet (3 mg, 7 mg, or 14 mg). It is approved for T2D, not for chronic weight management. It is convenient for patients who cannot or will not inject. It typically produces less weight loss than injectable semaglutide and substantially less than tirzepatide.

If your goal is glycaemic control and you have a strong preference against injections, Rybelsus is reasonable. If meaningful weight loss is a goal, an injectable (semaglutide 2.4 mg or tirzepatide) will outperform it.

Vial vs KwikPen — practical differences

Vials (2.5 mg, 5 mg) require drawing the dose into a syringe. They have a longer cold-chain shelf life and are generally easier to transport in volume. They suit patients who are comfortable with syringes or who have a caregiver assisting.

KwikPens are multi-dose, prefilled, single-patient pens. The user dials the prescribed dose and injects — no separate syringe is needed. Most patients prefer them for convenience, accuracy, and reduced anxiety about reconstitution. For higher doses (7.5 mg and above), KwikPens are the practical standard.

Cold chain in Indian conditions

Tirzepatide must be stored refrigerated at 2–8°C. Once removed, it can be kept at controlled room temperature (below 30°C) for a limited period — refer to the specific product insert for the exact window. In Indian summers, when ambient temperatures regularly exceed 35°C, and in monsoon humidity, practical steps matter:

For exact day-limits by formulation, flight rules, and what to do during a power cut, see our full guide to storing and travelling with a GLP-1 in Indian heat.

Prescription requirements

Tirzepatide is a Schedule H prescription drug in India. It can only be dispensed against a valid prescription from a registered medical practitioner. Reputable telemedicine providers, including Kaivo, conduct a structured clinical assessment, review your history and necessary investigations, and issue a prescription if appropriate. Buying tirzepatide without a prescription, or from unverified online sources, is illegal and unsafe — counterfeit GLP-1 products have been identified globally.

Who is Mounjaro most appropriate for?

Mounjaro is a strong fit for:

It is not appropriate for patients with type 1 diabetes, personal or family history of medullary thyroid carcinoma or MEN-2 (see our thyroid guide), pregnancy or breastfeeding, severe gastroparesis, or active pancreatitis.

Tirzepatide patent considerations in India

Tirzepatide's compound patent in India is currently expected to remain in force into the later part of this decade. Until then, Mounjaro is the only legitimate source of tirzepatide in the Indian market; any product marketed as "generic tirzepatide" available before patent expiry should be treated with extreme caution. Several Indian manufacturers have publicly indicated readiness to launch tirzepatide generics on or near expiry; until then, branded Mounjaro is the appropriate choice.

What to expect from a Kaivo consultation

Your AIIMS-trained Kaivo physician will review your history, current medications, relevant investigations (HbA1c, fasting lipids, kidney function, TSH, and others as indicated), screen for contraindications, and discuss whether tirzepatide is the right molecule for you — or whether semaglutide, oral therapy, or a non-pharmacological approach is more appropriate. Follow-up is structured around dose titration, side-effect management, and tracking the outcomes that matter: weight, waist circumference, HbA1c, blood pressure, and how you actually feel. If your loss flattens after a few months, that is usually a titration signal, not failure — see what to do when Mounjaro stalls. And because tirzepatide treats a chronic condition rather than curing it, we plan for the end from the start — here's how to stop Mounjaro without regaining weight.

This is a medical decision, not a consumer purchase. Treating it with the seriousness it deserves is the first step.

Mounjaro is a registered trademark of Eli Lilly. Kaivo is not affiliated with Eli Lilly. We provide consultations and may prescribe generic tirzepatide or branded Mounjaro based on availability and clinical judgment.

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
  2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503–515.
  3. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613–626.
  4. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
  5. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP-2). Lancet. 2021;397(10278):971–984.